Home > Quotes > VRX

Valeant Pharmaceuticals International, Inc. Stock Quote & Summary Data

VRX 
$123.52
*  
0.84
0.68%
Get VRX Alerts
*Delayed - data as of Jul. 25, 2014  -  Find a broker to begin trading VRX now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
1 Year Target: 162.5
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today's trading to the average daily volume. 3,179,769
Previous Close: $ 124.36
52 Week High /Low: $ 153.10 / $ 90.925
Market cap "Market Capitalization" is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. �Market Capitalization� is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 41,202,838,144
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 14.36
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -2.60
Annualized dividend $ 0.38
Ex Dividend Date Aug. 30, 2010
Dividend Payment Date Oct. 4, 2010
Current Yield 0.31 %
Beta 0.8

Intraday Chart

Company Description (as filed with the SEC)

Biovail Corporation (“Biovail”) was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act (the “CBCA”) effective June 29, 2005. On September 28, 2010 (the “Merger Date”), Biovail completed the acquisition of Valeant Pharmaceuticals International (“Valeant”) through a wholly-owned subsidiary pursuant to an Agreement and Plan of Merger, dated as of June 20, 2010, with Valeant surviving as a wholly-owned subsidiary of Biovail (the “Merger”). In connection with the Merger, Biovail was renamed “Valeant Pharmaceuticals International, Inc.  ... More ...  

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?